Results 1 to 10 of about 12,125,335 (363)

Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases

open access: yesGut microbes, 2022
The human intestine hosts diverse microbial communities that play a significant role in maintaining gut-skin homeostasis. When the relationship between gut microbiome and the immune system is impaired, subsequent effects can be triggered on the skin ...
Md. Rayhan Mahmud   +10 more
semanticscholar   +1 more source

Single-cell RNA-seq reveals fibroblast heterogeneity and increased mesenchymal fibroblasts in human fibrotic skin diseases

open access: yesNature Communications, 2021
Fibrotic skin disease represents a major global healthcare burden, characterized by fibroblast hyperproliferation and excessive accumulation of extracellular matrix.
Cheng-Cheng Deng   +10 more
semanticscholar   +1 more source

Advances in the study of macrophage polarization in inflammatory immune skin diseases

open access: yesJournal of Inflammation, 2023
When exposed to various microenvironmental stimuli, macrophages are highly plastic and primarily polarized into the pro-inflammatory M1-type and the anti-inflammatory M2-type, both of which perform almost entirely opposing functions.
Tingting Xia   +10 more
semanticscholar   +1 more source

The role of short-chain fatty acids in inflammatory skin diseases

open access: yesFrontiers in Microbiology, 2023
Short-chain fatty acids (SCFAs) are metabolites of gut microbes that can modulate the host inflammatory response, and contribute to health and homeostasis.
Xian-jun Xiao   +13 more
semanticscholar   +1 more source

Polymeric Nanoparticles as Tunable Nanocarriers for Targeted Delivery of Drugs to Skin Tissues for Treatment of Topical Skin Diseases

open access: yesPharmaceutics, 2023
The topical route is the most appropriate route for the targeted delivery of drugs to skin tissues for the treatment of local skin diseases; however, the stratum corneum (SC), the foremost layer of the skin, acts as a major barrier.
E. A. Madawi   +7 more
semanticscholar   +1 more source

TRPV1: A promising therapeutic target for skin aging and inflammatory skin diseases

open access: yesFrontiers in Pharmacology, 2023
TRPV1 is a non-selective channel receptor widely expressed in skin tissues, including keratinocytes, peripheral sensory nerve fibers and immune cells. It is activated by a variety of exogenous or endogenous inflammatory mediators, triggering neuropeptide
Tengfei Xiao   +3 more
semanticscholar   +1 more source

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

open access: yesBiomolecules, 2023
Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2
Henning Olbrich   +4 more
semanticscholar   +1 more source

Quality of life and stigmatization in people with skin diseases in Europe: A large survey from the ‘burden of skin diseases’ EADV project

open access: yesJournal of the European Academy of Dermatology and Venereology, 2023
Several large studies on the burden of skin diseases have been performed in patients recruited in hospitals or clinical centres, thus missing people with skin diseases who do not undergo a clinical consultation.
P. Gisondi   +8 more
semanticscholar   +1 more source

Prevalence of most common skin diseases in Europe: a population‐based study

open access: yesJournal of the European Academy of Dermatology and Venereology, 2022
The assessment of the prevalence of diseases is of primary importance in planning health policies. No complete data on the prevalence of skin diseases across European countries are available.
M. Richard   +8 more
semanticscholar   +1 more source

A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy

open access: yesСовременная ревматология, 2021
The article discusses the common pathogenetic pathways of autoimmune skin diseases – psoriasis and vitiligo. Currently proposed treatments for vitiligo do not significantly reduce or completely restore skin pigmentation. The use of adalimumab for 6 years
N. S. Rudneva   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy